Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Ruud Dings

TitleAssistant Professor
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentRadiation Oncology, College of Medicine
DivisionRadiation Oncology Faculty
Address4104 Outpatient Circle
Mail Slot # 771
Little Rock AR 72205
Phone501-526-7876
vCardDownload vCard

    Collapse Research Funds 
    Collapse research activities
    R01CA238025     (DINGS, RUUD)Aug 13, 2019 - Jul 31, 2024
    NIH/Nat. Cancer Institute - Pass Through: University of Arkansas at Fayetteville
    Determination of functional and molecular biomarkers of treatment resistance with multimodal optical spectroscopy- Resubmission
    Role: Principal Investigator

    S10 OD026736     (MACKINTOSH, SAMUEL)Aug 1, 2019 - Jul 31, 2020
    NIH/National Institutes of Health
    Q Exactive HF-X Hybrid Quadrupole Orbitrap Mass Spectrometer
    Role: Co-Investigator

    P20GM103625     (SMELTZER, MARK S)Aug 15, 2012 - Apr 30, 2022
    NIH/NIGMS
    Center for Microbial Pathogenesis and Host Inflammatory Responses
    Role: Co-Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions. Don't see publications published under other names? Login to add alternative names.
    List All   |   Timeline
    1. Jenkins SV, Robeson MS, Griffin RJ, Quick CM, Siegel ER, Cannon MJ, Vang KB, Dings RPM. Gastrointestinal Tract Dysbiosis Enhances Distal Tumor Progression through Suppression of Leukocyte Trafficking. Cancer Res. 2019 Dec 01; 79(23):5999-6009. PMID: 31591154.
      View in: PubMed
    2. Jenkins SV, Nedosekin DA, Shaulis BJ, Wang T, Jamshidi-Parsian A, Pollock ED, Chen J, Dings RPM, Griffin RJ. Enhanced Photothermal Treatment Efficacy and Normal Tissue Protection via Vascular Targeted Gold Nanocages. Nanotheranostics. 2019; 3(2):145-155. PMID: 31008023.
      View in: PubMed
    3. Paidi SK, Diaz PM, Dadgar S, Jenkins SV, Quick CM, Griffin RJ, Dings RPM, Rajaram N, Barman I. Label-Free Raman Spectroscopy Reveals Signatures of Radiation Resistance in the Tumor Microenvironment. Cancer Res. 2019 04 15; 79(8):2054-2064. PMID: 30819665.
      View in: PubMed
    4. Boysen G, Jamshidi-Parsian A, Davis MA, Siegel ER, Simecka CM, Kore RA, Dings RPM, Griffin RJ. Glutaminase inhibitor CB-839 increases radiation sensitivity of lung tumor cells and human lung tumor xenografts in mice. Int J Radiat Biol. 2019 04; 95(4):436-442. PMID: 30557074.
      View in: PubMed
    5. Jenkins SV, Vang KB, Gies A, Griffin RJ, Jun SR, Nookaew I, Dings RPM. Sample storage conditions induce post-collection biases in microbiome profiles. BMC Microbiol. 2018 12 27; 18(1):227. PMID: 30591021.
      View in: PubMed
    6. Vargas I, Alhallak K, Kolenc OI, Jenkins SV, Griffin RJ, Dings RPM, Rajaram N, Quinn KP. Rapid quantification of mitochondrial fractal dimension in individual cells. Biomed Opt Express. 2018 Nov 01; 9(11):5269-5279. PMID: 30460127.
      View in: PubMed
    7. Nowak-Sliwinska P, Alitalo K, Allen E, Anisimov A, Aplin AC, Auerbach R, Augustin HG, Bates DO, van Beijnum JR, Bender RHF, Bergers G, Bikfalvi A, Bischoff J, Böck BC, Brooks PC, Bussolino F, Cakir B, Carmeliet P, Castranova D, Cimpean AM, Cleaver O, Coukos G, Davis GE, De Palma M, Dimberg A, Dings RPM, Djonov V, Dudley AC, Dufton NP, Fendt SM, Ferrara N, Fruttiger M, Fukumura D, Ghesquière B, Gong Y, Griffin RJ, Harris AL, Hughes CCW, Hultgren NW, Iruela-Arispe ML, Irving M, Jain RK, Kalluri R, Kalucka J, Kerbel RS, Kitajewski J, Klaassen I, Kleinmann HK, Koolwijk P, Kuczynski E, Kwak BR, Marien K, Melero-Martin JM, Munn LL, Nicosia RF, Noel A, Nurro J, Olsson AK, Petrova TV, Pietras K, Pili R, Pollard JW, Post MJ, Quax PHA, Rabinovich GA, Raica M, Randi AM, Ribatti D, Ruegg C, Schlingemann RO, Schulte-Merker S, Smith LEH, Song JW, Stacker SA, Stalin J, Stratman AN, Van de Velde M, van Hinsbergh VWM, Vermeulen PB, Waltenberger J, Weinstein BM, Xin H, Yetkin-Arik B, Yla-Herttuala S, Yoder MC, Griffioen AW. Consensus guidelines for the use and interpretation of angiogenesis assays. Angiogenesis. 2018 08; 21(3):425-532. PMID: 29766399.
      View in: PubMed
    8. Diaz PM, Jenkins SV, Alhallak K, Semeniak D, Griffin RJ, Dings RPM, Rajaram N. Quantitative diffuse reflectance spectroscopy of short-term changes in tumor oxygenation after radiation in a matched model of radiation resistance. Biomed Opt Express. 2018 Aug 01; 9(8):3794-3804. PMID: 30338156.
      View in: PubMed
    9. Dings RPM, Cannon M, Vang KB. Design of Gold Nanoparticles in Dendritic Cell-based Vaccines. Particle and particle systems characterization. 2018; (35):1-12.
    10. Lee DE, Alhallak K, Jenkins SV, Vargas I, Greene NP, Quinn KP, Griffin RJ, Dings RPM, Rajaram N. A Radiosensitizing Inhibitor of HIF-1 alters the Optical Redox State of Human Lung Cancer Cells In Vitro. Sci Rep. 2018 06 11; 8(1):8815. PMID: 29891977.
      View in: PubMed
    11. Kore RA, Edmondson JL, Jenkins SV, Jamshidi-Parsian A, Dings RPM, Reyna NS, Griffin RJ. Hypoxia-derived exosomes induce putative altered pathways in biosynthesis and ion regulatory channels in glioblastoma cells. Biochem Biophys Rep. 2018 Jul; 14:104-113. PMID: 29872742.
      View in: PubMed
    12. Dings RPM, Miller MC, Griffin RJ, Mayo KH. Galectins as Molecular Targets for Therapeutic Intervention. Int J Mol Sci. 2018 Mar 19; 19(3). PMID: 29562695.
      View in: PubMed
    13. Koonce NA, Griffin RJ, Dings RPM. Galectin-1 Inhibitor OTX008 Induces Tumor Vessel Normalization and Tumor Growth Inhibition in Human Head and Neck Squamous Cell Carcinoma Models. Int J Mol Sci. 2017 Dec 09; 18(12). PMID: 29232825.
      View in: PubMed
    14. Jenkins SV, Nima ZA, Vang KB, Kannarpady G, Nedosekin DA, Zharov VP, Griffin RJ, Biris AS, Dings RPM. Triple-negative breast cancer targeting and killing by EpCAM-directed, plasmonically active nanodrug systems. NPJ Precis Oncol. 2017; 1(1):27. PMID: 29872709.
      View in: PubMed
    15. Koonce NA, Juratli MA, Cai C, Sarimollaoglu M, Menyaev YA, Dent J, Quick CM, Dings RPM, Nedosekin D, Zharov V, Griffin RJ. Real-time monitoring of circulating tumor cell (CTC) release after nanodrug or tumor radiotherapy using in vivo flow cytometry. Biochem Biophys Res Commun. 2017 10 21; 492(3):507-512. PMID: 28822765.
      View in: PubMed
    16. Vang KB, Safina I, Darrigues E, Nedosekin D, Nima ZA, Majeed W, Watanabe F, Kannarpady G, Kore RA, Casciano D, Zharov VP, Griffin RJ, Dings RPM, Biris AS. Modifying Dendritic Cell Activation with Plasmonic Nano Vectors. Sci Rep. 2017 07 14; 7(1):5513. PMID: 28710434.
      View in: PubMed
    17. Alhallak K, Jenkins SV, Lee DE, Greene NP, Quinn KP, Griffin RJ, Dings RPM, Rajaram N. Optical imaging of radiation-induced metabolic changes in radiation-sensitive and resistant cancer cells. J Biomed Opt. 2017 06 01; 22(6):60502. PMID: 28622395.
      View in: PubMed
    18. Jenkins SV, Nedosekin DA, Miller EK, Zharov VP, Dings RPM, Chen J, Griffin RJ. Galectin-1-based tumour-targeting for gold nanostructure-mediated photothermal therapy. Int J Hyperthermia. 2018 02; 34(1):19-29. PMID: 28540812.
      View in: PubMed
    19. Griffin RJ, Dings RPM, Makhoul I. Further rationale for optimal combined modality treatments. Oncotarget. 2017 04 18; 8(16):25831-25832. PMID: 28415727.
      View in: PubMed
    20. Koonce NA, Levy J, Hardee ME, Jamshidi-Parsian A, Vang KB, Sharma S, Raleigh JA, Dings RP, Griffin RJ. Targeting Artificial Tumor Stromal Targets for Molecular Imaging of Tumor Vascular Hypoxia. PLoS One. 2015; 10(8):e0135607. PMID: 26308944.
      View in: PubMed
    21. Koonce NA, Quick CM, Hardee ME, Jamshidi-Parsian A, Dent JA, Paciotti GF, Nedosekin D, Dings RP, Griffin RJ. Combination of Gold Nanoparticle-Conjugated Tumor Necrosis Factor-a and Radiation Therapy Results in a Synergistic Antitumor Response in Murine Carcinoma Models. Int J Radiat Oncol Biol Phys. 2015 Nov 01; 93(3):588-96. PMID: 26461001.
      View in: PubMed
    22. Läppchen T, Dings RP, Rossin R, Simon JF, Visser TJ, Bakker M, Walhe P, van Mourik T, Donato K, van Beijnum JR, Griffioen AW, Lub J, Robillard MS, Mayo KH, Grüll H. Novel analogs of antitumor agent calixarene 0118: Synthesis, cytotoxicity, click labeling with 2-[(18)F]fluoroethylazide, and in vivo evaluation. Eur J Med Chem. 2015 Jan 07; 89:279-95. PMID: 25462244.
      View in: PubMed
    23. Dings RP, Haseman JR, Leslie DB, Luong M, Dunn DL, Mayo KH. Bacterial membrane disrupting dodecapeptide SC4 improves survival of mice challenged with Pseudomonas aeruginosa. Biochim Biophys Acta. 2013 Jun; 1830(6):3454-7. PMID: 23403135.
      View in: PubMed
    24. Dings RP, Levine JI, Brown SG, Astorgues-Xerri L, MacDonald JR, Hoye TR, Raymond E, Mayo KH. Polycationic calixarene PTX013, a potent cytotoxic agent against tumors and drug resistant cancer. Invest New Drugs. 2013 Oct; 31(5):1142-50. PMID: 23392775.
      View in: PubMed
    25. Dings RP, Kumar N, Miller MC, Loren M, Rangwala H, Hoye TR, Mayo KH. Structure-based optimization of angiostatic agent 6DBF7, an allosteric antagonist of galectin-1. J Pharmacol Exp Ther. 2013 Mar; 344(3):589-99. PMID: 23232447.
      View in: PubMed
    26. Dings RP, Miller MC, Nesmelova I, Astorgues-Xerri L, Kumar N, Serova M, Chen X, Raymond E, Hoye TR, Mayo KH. Antitumor agent calixarene 0118 targets human galectin-1 as an allosteric inhibitor of carbohydrate binding. J Med Chem. 2012 Jun 14; 55(11):5121-9. PMID: 22575017.
      View in: PubMed
    27. Griffin RJ, Koonce NA, Dings RP, Siegel E, Moros EG, Bräuer-Krisch E, Corry PM. Microbeam radiation therapy alters vascular architecture and tumor oxygenation and is enhanced by a galectin-1 targeted anti-angiogenic peptide. Radiat Res. 2012 Jun; 177(6):804-12. PMID: 22607585.
      View in: PubMed
    28. Song CW, Lee H, Dings RP, Williams B, Powers J, Santos TD, Choi BH, Park HJ. Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells. Sci Rep. 2012; 2:362. PMID: 22500211.
      View in: PubMed
    29. Apana SM, Griffin RJ, Koonce NA, Webber JS, Dings RPM, Mayo KH, Berridge MS. . Synthesis of [18F]anginex with high specific activity [18F]fluorobenzaldehyde for targeting angiogenic activity in solid tumors. J Label Compd Radiopharm. 2011; 6(54):708-713.
    30. Dings RP, Vang KB, Castermans K, Popescu F, Zhang Y, Oude Egbrink MG, Mescher MF, Farrar MA, Griffioen AW, Mayo KH. Enhancement of T-cell-mediated antitumor response: angiostatic adjuvant to immunotherapy against cancer. Clin Cancer Res. 2011 May 15; 17(10):3134-45. PMID: 21252159.
      View in: PubMed
    31. Dings RP, Loren ML, Zhang Y, Mikkelson S, Mayo KH, Corry P, Griffin RJ. Tumour thermotolerance, a physiological phenomenon involving vessel normalisation. Int J Hyperthermia. 2011; 27(1):42-52. PMID: 21204622.
      View in: PubMed
    32. Dings RP, Van Laar ES, Loren M, Webber J, Zhang Y, Waters SJ, Macdonald JR, Mayo KH. Inhibiting tumor growth by targeting tumor vasculature with galectin-1 antagonist anginex conjugated to the cytotoxic acylfulvene, 6-hydroxylpropylacylfulvene. Bioconjug Chem. 2010 Jan; 21(1):20-7. PMID: 20020769.
      View in: PubMed
    33. Griffin RJ, Dings RP, Jamshidi-Parsian A, Song CW. Mild temperature hyperthermia and radiation therapy: role of tumour vascular thermotolerance and relevant physiological factors. Int J Hyperthermia. 2010; 26(3):256-63. PMID: 20210610.
      View in: PubMed
    34. Saarinen NM, Wärri A, Dings RP, Airio M, Smeds AI, Mäkelä S. Dietary lariciresinol attenuates mammary tumor growth and reduces blood vessel density in human MCF-7 breast cancer xenografts and carcinogen-induced mammary tumors in rats. Int J Cancer. 2008 Sep 01; 123(5):1196-204. PMID: 18528864.
      View in: PubMed
    35. Dings RP, Haseman JR, Mayo KH. Probing structure-activity relationships in bactericidal peptide betapep-25. Biochem J. 2008 Aug 15; 414(1):143-50. PMID: 18489259.
      View in: PubMed
    36. Dings RP, Van Laar ES, Webber J, Zhang Y, Griffin RJ, Waters SJ, MacDonald JR, Mayo KH. Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulven. Cancer Lett. 2008 Jul 08; 265(2):270-80. PMID: 18378392.
      View in: PubMed
    37. Dings RP, Mayo KH. A journey in structure-based drug discovery: from designed peptides to protein surface topomimetics as antibiotic and antiangiogenic agents. Acc Chem Res. 2007 Oct; 40(10):1057-65. PMID: 17661438.
      View in: PubMed
    38. Dings RP, Loren M, Heun H, McNiel E, Griffioen AW, Mayo KH, Griffin RJ. Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res. 2007 Jun 01; 13(11):3395-402. PMID: 17545548.
      View in: PubMed
    39. Schumacher JJ, Dings RP, Cosin J, Subramanian IV, Auersperg N, Ramakrishnan S. Modulation of angiogenic phenotype alters tumorigenicity in rat ovarian epithelial cells. Cancer Res. 2007 Apr 15; 67(8):3683-90. PMID: 17440080.
      View in: PubMed
    40. Amano M, Suzuki M, Andoh S, Monzen H, Terai K, Williams B, Song CW, Mayo KH, Hasegawa T, Dings RP, Griffin RJ. Antiangiogenesis therapy using a novel angiogenesis inhibitor, anginex, following radiation causes tumor growth delay. Int J Clin Oncol. 2007 Feb; 12(1):42-7. PMID: 17380440.
      View in: PubMed
    41. Chen X, Dings RP, Nesmelova I, Debbert S, Haseman JR, Maxwell J, Hoye TR, Mayo KH. Topomimetics of amphipathic beta-sheet and helix-forming bactericidal peptides neutralize lipopolysaccharide endotoxins. J Med Chem. 2006 Dec 28; 49(26):7754-65. PMID: 17181157.
      View in: PubMed
    42. Hellebrekers DM, Castermans K, Viré E, Dings RP, Hoebers NT, Mayo KH, Oude Egbrink MG, Molema G, Fuks F, van Engeland M, Griffioen AW. Epigenetic regulation of tumor endothelial cell anergy: silencing of intercellular adhesion molecule-1 by histone modifications. Cancer Res. 2006 Nov 15; 66(22):10770-7. PMID: 17108113.
      View in: PubMed
    43. Thijssen VL, Postel R, Brandwijk RJ, Dings RP, Nesmelova I, Satijn S, Verhofstad N, Nakabeppu Y, Baum LG, Bakkers J, Mayo KH, Poirier F, Griffioen AW. Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci U S A. 2006 Oct 24; 103(43):15975-80. PMID: 17043243.
      View in: PubMed
    44. Griffin RJ, Molema G, Dings RP. Angiogenesis treatment, new concepts on the horizon. Angiogenesis. 2006; 9(2):67-72. PMID: 16964528.
      View in: PubMed
    45. Brandwijk RJ, Dings RP, van der Linden E, Mayo KH, Thijssen VL, Griffioen AW. Anti-angiogenesis and anti-tumor activity of recombinant anginex. Biochem Biophys Res Commun. 2006 Oct 27; 349(3):1073-8. PMID: 16970922.
      View in: PubMed
    46. Dings RP, Chen X, Hellebrekers DM, van Eijk LI, Zhang Y, Hoye TR, Griffioen AW, Mayo KH. Design of nonpeptidic topomimetics of antiangiogenic proteins with antitumor activities. J Natl Cancer Inst. 2006 Jul 05; 98(13):932-6. PMID: 16818857.
      View in: PubMed
    47. van Beijnum JR, Dings RP, van der Linden E, Zwaans BM, Ramaekers FC, Mayo KH, Griffioen AW. Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature. Blood. 2006 Oct 01; 108(7):2339-48. PMID: 16794251.
      View in: PubMed
    48. Dirkx AE, oude Egbrink MG, Castermans K, van der Schaft DW, Thijssen VL, Dings RP, Kwee L, Mayo KH, Wagstaff J, Bouma-ter Steege JC, Griffioen AW. Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J. 2006 Apr; 20(6):621-30. PMID: 16581970.
      View in: PubMed
    49. Brandwijk RJ, Nesmelova I, Dings RP, Mayo KH, Thijssen VL, Griffioen AW. Cloning an artificial gene encoding angiostatic anginex: From designed peptide to functional recombinant protein. Biochem Biophys Res Commun. 2005 Aug 12; 333(4):1261-8. PMID: 15979575.
      View in: PubMed
    50. Dings RP, Williams BW, Song CW, Griffioen AW, Mayo KH, Griffin RJ. Anginex synergizes with radiation therapy to inhibit tumor growth by radiosensitizing endothelial cells. Int J Cancer. 2005 Jun 10; 115(2):312-9. PMID: 15688384.
      View in: PubMed
    51. Thijssen VL, Brandwijk RJ, Dings RP, Griffioen AW. Angiogenesis gene expression profiling in xenograft models to study cellular interactions. Exp Cell Res. 2004 Oct 01; 299(2):286-93. PMID: 15350528.
      View in: PubMed
    52. Wild R, Dings RP, Subramanian I, Ramakrishnan S. Carboplatin selectively induces the VEGF stress response in endothelial cells: Potentiation of antitumor activity by combination treatment with antibody to VEGF. Int J Cancer. 2004 Jun 20; 110(3):343-51. PMID: 15095298.
      View in: PubMed
    53. Wild R, Yokoyama Y, Dings RP, Ramakrishnan S. VEGF-DT385 toxin conjugate inhibits mammary adenocarcinoma development in a transgenic mouse model of spontaneous tumorigenesis. Breast Cancer Res Treat. 2004 May; 85(2):161-71. PMID: 15111774.
      View in: PubMed
    54. Mayo KH, Dings RP, Flader C, Nesmelova I, Hargittai B, van der Schaft DW, van Eijk LI, Walek D, Haseman J, Hoye TR, Griffioen AW. Design of a partial peptide mimetic of anginex with antiangiogenic and anticancer activity. J Biol Chem. 2003 Nov 14; 278(46):45746-52. PMID: 12947097.
      View in: PubMed
    55. Dings RP, Arroyo MM, Lockwood NA, van Eijk LI, Haseman JR, Griffioen AW, Mayo KH. Beta-sheet is the bioactive conformation of the anti-angiogenic anginex peptide. Biochem J. 2003 Jul 01; 373(Pt 1):281-8. PMID: 12708970.
      View in: PubMed
    56. Dings RP, van der Schaft DW, Hargittai B, Haseman J, Griffioen AW, Mayo KH. Anti-tumor activity of the novel angiogenesis inhibitor anginex. Cancer Lett. 2003 May 08; 194(1):55-66. PMID: 12706859.
      View in: PubMed
    57. Dings RP, Yokoyama Y, Ramakrishnan S, Griffioen AW, Mayo KH. The designed angiostatic peptide anginex synergistically improves chemotherapy and antiangiogenesis therapy with angiostatin. Cancer Res. 2003 Jan 15; 63(2):382-5. PMID: 12543791.
      View in: PubMed
    58. Dings RP, Nesmelova I, Griffioen AW, Mayo KH. Discovery and development of anti-angiogenic peptides: A structural link. Angiogenesis. 2003; 6(2):83-91. PMID: 14739615.
      View in: PubMed
    59. van der Schaft DW, Dings RP, de Lussanet QG, van Eijk LI, Nap AW, Beets-Tan RG, Bouma-Ter Steege JC, Wagstaff J, Mayo KH, Griffioen AW. The designer anti-angiogenic peptide anginex targets tumor endothelial cells and inhibits tumor growth in animal models. FASEB J. 2002 Dec; 16(14):1991-3. PMID: 12397082.
      View in: PubMed
    60. Tromp SC, oude Egbrink MG, Dings RP, van Velzen S, Slaaf DW, Hillen HF, Tangelder GJ, Reneman RS, Griffioen AW. Tumor angiogenesis factors reduce leukocyte adhesion in vivo. Int Immunol. 2000 May; 12(5):671-6. PMID: 10784613.
      View in: PubMed
    Dings's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _